Merus N.V. (MRUS): A Bull Case Theory
We came across a bullish thesis on Merus N.V. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on MRUS.
Merus N.v. (MRUS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 3,542,500 | $333,526,375 | +13% | 4.31% |
| 2. | Commodore Capital Egen Atkinson And Michael Kramarz | 3,525,000 | $331,878,750 | 16.2% | |
| 3. | Deerfield Management James E. Flynn | 3,046,916 | $286,867,141 | -10% | 4.38% |
| 4. | HBK Investments David Costen Haley | 2,850,000 | $268,327,500 | 2.94% | |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,674,167 | $157,622,823 | +9% | 0.74% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $97.00 | 66,264 | $6,427,608.00 | 72,013,065 | 2025-12-19 | Filing | |
| $97.00 | 212,177 | $20,581,169.00 | 71,946,801 | 2025-12-18 | Filing | |
| $97.00 | 150,795 | $14,627,115.00 | 71,734,624 | 2025-12-17 | Filing | |
| $97.00 | 120,752 | $11,712,944.00 | 71,583,829 | 2025-12-16 | Filing | |
| $14.38 | 14,706 | $211,431.10 | 40,576 | 2022-11-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $96.10 | 1,700 | $163,370.00 | 11,002 | 2025-11-26 | Filing | |
| $95.92 | 8,300 | $796,136.00 | 11,002 | 2025-11-25 | Filing | |
| $60.00 | 25,000 | $1,500,000.00 | 0 | 2025-07-17 | Filing | |
| $55.00 | 16,805 | $924,275.00 | 0 | 2025-07-10 | Filing | |
| $55.00 | 6,695 | $368,225.00 | 0 | 2025-07-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,373,770 | $411,790,446 | 11.71% | |
| 2. | 2,810,935 | $264,649,564 | 0.01% | |
| 3. | 2,172,015 | $204,495,213 | 0% | |
| 4. | 2,132,489 | $200,773,839 | 0.84% | |
| 5. | 2,025,277 | $190,679,830 | 2.35% |
News See All
Merus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth Potential
Merus N.V. (NASDAQ:MRUS) ranks among the best biotech stocks to buy. On September 17, Barclays began coverage of Merus N.V. (NASDAQ:MRUS) with a price target of $112 and an Overweight rating.
Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium
The companies said the purchase price stands at a 41-percent premium over Merus NV’s (NASDAQ:MRUS) $68.89 closing price on September 26, and approximately 44 percent over its 30-day volume-weighted ...
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS)
Merus N.V. (NASDAQ:MRUS) is one of the Best All-Time High Stocks to Buy According to Analysts. On June 10, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Merus N.V.
10 Best All-Time High Stocks to Buy According to Analysts
On July 31, Mike Wilson, Morgan Stanley's chief US equity strategist, joined CNBC Television to discuss the market performance amidst inflation concerns.
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III
Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts.
16 Most Promising Stocks According to Wall Street Analysts
On July 3, Scott Wren, Wells Fargo senior global market strategist, and Adam Crisafulli, Vital Knowledge founder, joined 'Closing Bell Overtime' on CNBC to talk about the current market conditions.
Why Merus N.V. (MRUS) Crashed On Wednesday
We recently published a list of Investors Are Dumping These 10 Stocks.
BofA Maintains Buy Rating on Merus (MRUS), Lifts PT
The decision follows Merus' highly favorable Phase 2 trial results for the combination of petosemtamab and pembrolizumab in treating first-line head and neck squamous cell carcinoma/HNSCC.
Hedge Fund Resource Center Billionaire Hedge Funds
